Exchange: NASDAQ·Updated 07:59 PM EDT

VKTX News

News
all
press releases
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
Viking Therapeutics, Inc. (VKTX) closed at $33.98 in the latest trading session, marking a +1.43% move from the prior day.
Zacks
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong
Key PointsViking Therapeutics' shares could soar as it makes progress with its leading candidates...
Nasdaq News: Markets
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics to Participate at Upcoming Investor Conferences Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, Sept. 2, 2026 SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage...
PR Newswire
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3
Investors are now awaiting results from an early-stage study of VK2735 testing different ways to keep weight off after an initial course of treatment.
Stocktwits
Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.
Zacks
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.
Key PointsVK2735 is Viking's lead candidate for obesity with dual-formulation potential...
Nasdaq News: Markets
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?
Key PointsViking's strong cash position funds operations through major milestones in 2027 and 2028...
Nasdaq News: Markets

Advertisement|Remove ads.